Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions
Kailera Therapeutics and Hengrui Pharma will present clinical data for ribupatide, a GLP-1/GIP receptor dual agonist, at the 86th Scientific Sessions of the American Diabetes Association in June 2026. Hengrui will present data from a Phase 2 trial of oral ribupatide in adults with obesity, while Kailera will present data from a Phase 1 bridging study of the injectable form. The ribupatide franchise includes both oral and injectable formulations, with the injectable form currently in global Phase 3 trials.
Key figures
- Drug Name
- ribupatide (KAI-9531)
- Phase Of Trial
- Phase 2 (oral), Phase 1 (injectable)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.